INTRODUCTION {#s1}
============

Central post-stroke pain (CPSP) is generally referred as pain originating from damage to the central nervous system after stroke. It was first documented as occurring in the limbs after a contra-lateral thalamic stroke[@r1]^)^. The pain was then described as a spontaneous pain, and a painful over-reaction to external stimulation resulting from lesions confined to the central nervous system[@r2]^)^. Although central pain after stroke was originally described as 'thalamic pain', it is currently recognized that strokes involving the sensory tracts in the various brain regions can produce pain similar to central pain[@r3], [@r4]^)^.

Because of a growing elderly population, treatments for CPSP have been gaining more attention[@r5],[@r6],[@r7],[@r8]^)^. Pain often has a negative impact on patient's quality of life[@r9]^)^. CPSP is mainly caused by cerebrovascular diseases, which are common among the elderly[@r10]^)^. The current mainstream treatment for CPSP control is pharmacology[@r11]^)^. However, CPSP is frequently persistent and pharmacological treatments have unpleasant side effects. This drives researchers to search for other techniques to control the pain of CPSP patients.

In recent decades, non-invasive physical modalities (NIPMs) have been extensively utilized in physical therapy[@r12], [@r13]^)^. They induce neuro-modulatory effects for either motor improvement or pain control[@r8], [@r14], [@r15]^)^. The term, NIPMs, refers to the techniques involving the application of physical modalities across the intact surface of the skin for treatment purposes such as pain relief[@r16], [@r17]^)^. NIPMs are mainly used by physicians, health professionals, or are self-administered by patient. Many NIPMs are safe, inexpensive, easy to operate, and have no profile of toxicity in long term use, e.g. transcutaneous electrical nerve stimulation (TENS)[@r17],[@r18],[@r19],[@r20]^)^.

NIPMs have been used for decades, little is known about their effects on the reduction of CPSP. This was our motives for exploring the antalgic effects of NIPMs on CPSP in a systematic review of clinical reports in order to summarize the efficacies of various NIPMs. To date, no study has systematically reviewed the clinical evidences to determine the antalgic effects of NIPMs on CPSP. This review should provide the most up-to-date profile of the effect of NIPMs used to control CPSP.

SUBJECTS AND METHODS {#s2}
====================

Clinical studies were searched in September 2015 using the following electronic databases: 1) Academic Search Premier (1975--present) ; 2) CINAHL Plus with full text (1937--present); 3) Medline Proquest (1966--present); 4) Medline Ovid SP(1946--present); 5) ProQuest Health and Medical Complete (1986--present); 6) Pubmed (1946--present); 7) Science Direct online (SODL; 1997--present); 8) Scopus (1823--present); 9) The Cochrane Library (1993--present); and 10) Web of Science (1955--present). The initial search was done using the search string, "central pain and stroke", for potential articles, and a second search was sequentially done using the other searching strings "treatment", "physical" or "non-pharmacological". The articles were screened by two independent reviewers. A third reviewer exercised when there were disagreements over the searched articles between the aforementioned two reviewers. The inclusion criteria were studies that had: 1) been published as a full clinical study in English; 2) investigated the antalgic effects of the treatments using the physical modalities after a stroke; 3) recorded outcomes as changes in the pain intensity. Initially, study title and abstract were used to search for potential studies which were further checked to identify the full published reports. The reference lists of retrieved or relevant articles were also screened for reports that were not identified through the electronic searches. Studies and/or comparisons were excluded if a treatment was invasive or a physical modality was not used for treatment purpose.

Information was extracted and trial outcome judgment was made. A statistically significant reduction on a visual analogue scale of pain at any time throughout a study was regarded as an effective outcome. A selected study was classified into one of four classes (Classes I to IV) with declining study quality according to the table of Evidence Classification Scheme for Therapeutic Interventions[@r21]^)^. All classified studies with various study quality in each NIPM were accumulated and rated using one of the three recommendation levels (Levels A to C) with declining evidence strength in alphabetic order[@r21]^)^.

RESULTS {#s3}
=======

Over 1,200 articles were identified by the first and second searches of the electronic databases ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Procedure of search and selection). Among them, 1,136 articles did not to meet the inclusion criteria. Only 85 full-published reports were potentially relevant for retrieval ([Fig. 1](#fig_001){ref-type="fig"}). Of the 85 reports, 67 were excluded due to invasive interventions including acupuncture (n=5), deep brain stimulation (DBS, n=12), spinal cord stimulation (SCS, n=7), electroconvulsive therapy (ECT, n=8), motor cortex stimulation (MCS, n=19), and surgery (n=16). Of the remaining 18 reports, EMG biofeedback (n=2) were excluded due to the intervention not as a physical treatment.

Only sixteen studies were eligible for the review. Five types of non-invasive modality intervention were found in the review: 1) caloric vestibular stimulation[@r22],[@r23],[@r24]^)^ (CVS; n=3), 2) heterotopic noxious conditioning stimulation[@r25]^)^ (HNCS; n=1), 3) transcutaneous electrical stimulation[@r26]^)^ (TENS; n=1), 4) transcranial direct current stimulation[@r27], [@r28]^)^ (TDCS; n=2), and 5) transcranial magnetic stimulation[@r29],[@r30],[@r31],[@r32],[@r33],[@r34],[@r35],[@r36],[@r37]^)^ (TMS, n=9). The CVS studies reported that the mean VAS scores was reduced 2.6 cm by the intervention[@r23]^)^, 4.0 cm in the 24 hours following the intervention[@r22]^)^, or 4.4 cm after 4 to 7 weeks of the intervention[@r24]^)^. The HNCS study reported that the mean VAS score was significantly increased 0.2 cm by the intervention[@r25]^)^. The TENS studies reported that three of the fifteen CPSP patients were reduced more than 20% of VAS scores after 23 to 30 months of the intervention[@r26]^)^. The TDCS studies reported that the mean VAS score was reduced 3.3 cm by the intervention[@r27]^)^ and significantly 1.2 cm after 3 weeks of the intervention[@r28]^)^. The TMS studies reported that the mean VAS scores were reduced 1.6 cm by the intervention[@r36]^)^, non-significantly 1.0 cm by 8 days of intervention[@r37]^)^, and significantly 3.2 cm by 2 weeks of the duration[@r34]^)^; and the other TMS studies reported that the VAS scores were significantly reduced 10.8% to 32.6% by the intervention[@r30],[@r31],[@r32],[@r33], [@r35]^)^. However, the most recent study of TMS reported no significant difference between the intervention and sham groups. The effects of CVS, HNCS, and TENS were rated as below Level C. TDCS and TMS were rated as Level B. These studies are summarized in [Table 1](#tbl_001){ref-type="table"}Table 1.Pain relieving effects of NIPMs intervention in CPSPStudySize^\*^Age^\*^ (y/o)Duration^\*^ (years)Baseline^\*^ (VAS; cm)Results^\*^ (VAS; cm)Class^\*\*^Rating^\*\*\*^I. Caloric vestibular stimulation1. McGeoch et al., 2009^22)^158.00.259.0−4.0 in 24 hoursIVBelow C2. McGeoch et al., 2008^23)^959.99.25.8−2.6III3. Ramachandran et al., 2007^24)^278.06.07.8−4.4 in 4 to 7 weeksIVII. Heterotopic noxious conditioning stimulation1. Tuveson et al., 2009^25)^1060.25.06.7+0.2 (SD)IIIBelow CIII. Transcutaneous electrical nerve stimulation1. Leijon et al., 1989^26)^1567.04.1NA\>−20%^†^ in 3/15 patients in 23 to 30 monthsIIIBelow CIV. Transcranial direct current stimulation1. Morishita et al., 2015^27)^172.00.756.0−3.3IVB1. Bae et al., 2014^28)^1451.112.24.3−1.2 in 3 weeks (SD; Sham: NSD) \[RCT\]IIV. Transcranial magnetic stimulation1. De Oliveira et al., 2014^29)^1155.05.36.8NSD from Sham in 1 to 10 days \[RCT\]IIB2. Hosomi et al., 2013^30)^2159.64.07.8−32.6%^†^(SD)IIIB3. Ohn et al., 2012^31)^2254.91.86.6−10.8%^†^(SD)III4. Goto et al., 2008^32)^1763.15.18.1−24.5%^†^ (SD)III5.Hirayama et al., 2006^33)^1259.44.7NA−22.8%^†^ (SD)III6. Khedr et al., 2005^34)^2452.31.58.6−3.2 in 2 weeks (SD; Sham: NSD) \[RCr\]III7. Lefaucheur et al., 2004^35)^12^††^54.6NANA−20.3%^†^ compared to Sham (SD) \[RCr\]III8. Lefaucheur et al., 2001a^36)^6^††^54.7NANA−1.6 (Sham: NSD) \[RCr\]III9. Lefaucheur et al., 2001b^37)^7^††^57.2NANA−1.0 in 8 days (NSD; Sham: NSD) \[RCr\]IIIi) \*Data presented as sample mean; \*\*Classification of study with declining evidence strength by number: I\>II\>III\>IV; \*\*\*Rating levels. ii) **†**Percentage from bassline VAS score; ††Thalamic pain. iii) NA: not available; NSD: no significant difference; SD: significant difference; RCr: randomized crossover design; RCT: randomized controlled trial; VAS: visual analogue scale.

DISCUSSION {#s4}
==========

Among the searched studies, TMS and TDCS were rated as Level B. Most of the studies investigated the effect of TMS on CPSP. The 5 Hz TMS reduced the VAS pain score by 22.8%[@r33]^)^ and 32.6%[@r30]^)^ from the baseline, and the 20 Hz[@r34]^)^ did the score by 3.2 cm. In contrast, The 10 Hz TMS reduced the VAS score by 10.8%[@r31]^)^ and 24.5%[@r32]^)^ from the baseline, or by 1.0[@r37]^)^ and 1.6[@r36]^)^ cm of VAS score. These results indicated that 5 Hz or 20 Hz TMS might be helpful for reducing CPSP more than 10 Hz TMS. However, the most recent study used 10 Hz TMS[@r29]^)^ and it reported there was no significant difference in pre-post CPSP. The inconsistency of the results among the 10 Hz TMS[@r29], [@r31], [@r32], [@r36], [@r37]^)^ may arise from the location of brain lesions, the areas of TMS, and the baseline measures of cortical activity. Study quality was also an issue as some[@r29], [@r36], [@r37]^)^ of the studies had small sizes.

TDCS was rated as B level. It reduced VAS scores by 1.2 (n=14)[@r28]^)^ and 3.3 (n=1)[@r27]^)^ cm at intensities of 2.0--2.5mA applied for 20 minutes. Among the CPSP patients with various brain lesions, TMS was found to be more effective than TDCS in 2 to 3 weeks of intervention \[3.2[@r34]^)^ vs. 1.2[@r28]^)^ VAS scores\]. In contrast, TDCS was found to be more effective than TMS just after the intervention \[3.3[@r27]^)^ vs. 1.6[@r36], [@r37]^)^ VAS scores\] when the lesion was only in the thalamus. This indicated that damage in various brain areas may influence the antalgic effects due to the introceptive circuits of pain control involved. Further to this evidence, the utilization of TMS and TDCS at different times may be an effective clinical strategy for eliciting an antalgic effect. However, the issue of poor study quality still exists, because of the small sample size (n=1) of the TDCS study[@r27]^)^. Clinically, TDCS might be appropriate for home care due to its portability for CPSP patients, and a guideline for remotely-supervised TDCS application in clinical trial has been announced[@r38]^)^.

HNCS, TENS and CVS were rated below C level. Poor study quality due to small sample size, various brain lesions, or no randomized control design was an issue with these studies. HNCS[@r26]^)^ with a modified submaximal effort tourniquet to induce ischemic discomfort induced a slight increase in CPSP in 15 minutes post-intervention, but the long-term effects were not investigated. TENS[@r27]^)^ of ether high (70 Hz) or low frequency (2 Hz) induced reductions in VAS pain scores of more than 20% from baseline in around 20% of the patients with short and long-term effects. Compared to TMS or TDCS, a TENS effect was only seen in some of the patients, but it is suggested for some patients with financial limits, because of its low-cost advantage. CVS with cold water (4° C) irrigated into external auditory canal for vestibular stimulation in one minute, realized VAS pain score reductions in the range of 2.6 to 4.4 cm[@r23],[@r24],[@r25]^)^, which observably better than those of TMS, 1.0 to 3.2[@r35], [@r37], [@r38]^)^ cm, and TDCS, 1.2 to 3.3[@r28], [@r29]^)^ cm. Although the CVS effects were promising, the temporary discomfort after the CVS might restrict its clinical application due to side-effects of vertigo and nystagmus. Due to low cost and simple application, CVS is still a valuable NIPM intervention for CPSP. However, CVS was only effective when the relay stations of introceptive circuits of pain control, such as the brain stem, were spared from stroke damage. These studies also had quality issues, such as small sample size (n=1[@r23]^)^, 2^25)^ or 9[@r24]^)^).

In summary, TMS and TDCS had higher levels of CPSP control efficacy than the other interventions. They showed better reduction of CPSP than TENS and HNCS. Compared to TMS and TDCS, the antalgic effect of low-cost CVS was promising but its clinical application may be restricted by post-application symptoms. TENS is a low-cost intervention, but the strength for its efficacy was poor and it was only effective for some of CPSP patients. The selected NIPMs with central approaches, such as CVS, TMS, or TDCS, might be beneficial for CPSP control. Due to inconsistent results and the relatively low quality of the current evidence for the efficacy of NIPMs, more evidence backed by higher quality studies is needed to establish the effects of NIPMs, especially their long-term effects on CPSP control.
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